Cite
HARVARD Citation
Phillips, T. et al. (2022). Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study. American journal of hematology. 97 (1), pp. E24-E27. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Phillips, T. et al. (2022). Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study. American journal of hematology. 97 (1), pp. E24-E27. [Online].